Targeted therapy with the T-cell - Engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival

✍ Scribed by Topp, Max S. (author);Kufer, Peter (author);Gökbuget, Nicola (author);Goebeler, Mariele (author);Klinger, Matthias (author);Neumann, Svenja (author);Horst, Heinz A. (author);Raff, Thorsten (author);Viardot, Andreas (author);Schmid, Mathias (author);Stelljes, Matthias (author);Schaich, Markus (author);Degenhard, Evelyn (author);Köhne-Volland, Rudolf (author);Brüggemann, Monika (author);Ottmann, Oliver (author);Pfeifer, Heike (author);Burmeister, Thomas (author);Nagorsen, Dirk (author);Schmidt, Margit (author);Lutterbuese, Ralf (author);Reinhardt, Carsten (author);Baeuerle, Patrick A. (author);Kneba, Michael (author);Einsele, Hermann (author);Riethmüller, Gert (author);Hoelzer, Dieter (author);Zugmaier, Gerhard (author);Bargou, Ralf C. (author)

• Book ID: 111658006
• Publisher: American Society of Clinical Oncology
• Year: 2011
• Tongue: English
• Weight: 135 KB
• Volume: 29
• Category: Article
• ISSN: 0732-183X
• DOI: 10.1200/jco.2010.32.7270